Chardan Capital Maintains Buy on CRISPR Therapeutics, Raises Price Target to $112
Chardan Capital Maintains Buy on CRISPR Therapeutics, Raises Price Target to $112
Chardan Capital維持對CRISPR Therapeutics的買入,將目標股價提高至112美元
Chardan Capital analyst Geulah Livshits maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $110 to $112.
查爾丹資本分析師吉拉·利夫希茨維持CRISPR Therapeutics(納斯達克股票代碼:CRSP)的買入並將目標股價從110美元上調至112美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。